Recent discoveries of newer drugs, such as the ALK tyrosine kinase inhibitors, led to a study comparing platinum-based chemotherapy’s efficacy against the novel alectinib in patients with ALK-positive NSCLC. This evidence concerns the gene ALK and non-small cell lung carcinoma.